Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2bn
Mallinckrodt has signed a deal to acquire US-based Sucampo Pharmaceuticals for about $1.2bn to add the latter’s constipation medication Amitiza (lubiprostone) and other commercial and development assets to its portfolio.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.